These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Hepatitis C virus- related cryoglobulinemic vasculitis: A review of the role of the new direct antiviral agents (DAAs) therapy. Mazzaro C; Dal Maso L; Mauro E; Visentini M; Tonizzo M; Gattei V; Andreone P; Pozzato G Autoimmun Rev; 2020 Aug; 19(8):102589. PubMed ID: 32540448 [TBL] [Abstract][Full Text] [Related]
4. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. Landau DA; Scerra S; Sene D; Resche-Rigon M; Saadoun D; Cacoub P J Rheumatol; 2010 Mar; 37(3):615-21. PubMed ID: 20110523 [TBL] [Abstract][Full Text] [Related]
5. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. Benstead TJ; Chalk CH; Parks NE Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010404. PubMed ID: 25525951 [TBL] [Abstract][Full Text] [Related]
6. [Hepatitis C virus-related cryoglobulinemic vasculitis with renal involvement: current possibilities of treatment]. Gordovskaia NB; Kozlovskaia LV; Milovanova SIu; Ignatova TM; Korotchaeva IuV Ter Arkh; 2013; 85(6):78-84. PubMed ID: 23866603 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. Emery JS; Kuczynski M; La D; Almarzooqi S; Kowgier M; Shah H; Wong D; Janssen HLA; Feld JJ Am J Gastroenterol; 2017 Aug; 112(8):1298-1308. PubMed ID: 28291241 [TBL] [Abstract][Full Text] [Related]
8. PegIFNα/ribavirin/protease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis. Saadoun D; Resche Rigon M; Pol S; Thibault V; Blanc F; Pialoux G; Karras A; Bazin-Kara D; Cazorla C; Vittecoq D; Musset L; Peltier J; Decaux O; Ziza JM; Lambotte O; Cacoub P J Hepatol; 2015 Jan; 62(1):24-30. PubMed ID: 25135864 [TBL] [Abstract][Full Text] [Related]
9. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. Levine JW; Gota C; Fessler BJ; Calabrese LH; Cooper SM J Rheumatol; 2005 Jun; 32(6):1164-7. PubMed ID: 15940780 [TBL] [Abstract][Full Text] [Related]
10. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Dammacco F; Lauletta G; Vacca A Clin Exp Med; 2023 Jun; 23(2):255-272. PubMed ID: 35348938 [TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review. Francesca Donato M; Banfi G; Cresseri D; Battista Fogazzi G; Martin P; Messa P; Fabrizi F Int J Artif Organs; 2013 May; 36(5):367-72. PubMed ID: 23446762 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of different antiviral treatment protocols in HCV related cryoglobulinemic vasculitis. Allam WR; Hegazy MT; Hussein MA; Zoheir N; Quartuccio L; El-Khamisy SF; Ragab G Sci Rep; 2024 May; 14(1):11840. PubMed ID: 38782988 [TBL] [Abstract][Full Text] [Related]
13. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Cacoub P; Saadoun D; Limal N; Sene D; Lidove O; Piette JC Arthritis Rheum; 2005 Mar; 52(3):911-5. PubMed ID: 15751068 [TBL] [Abstract][Full Text] [Related]
14. The dilemma of treating hepatitis C virus-associated cryoglobulinemia. Roccatello D; Fenoglio R; Sciascia S Curr Opin Rheumatol; 2019 Sep; 31(5):499-504. PubMed ID: 31090590 [TBL] [Abstract][Full Text] [Related]
15. The challenge of treating hepatitis C virus-associated cryoglobulinemic vasculitis in the era of anti-CD20 monoclonal antibodies and direct antiviral agents. Roccatello D; Sciascia S; Rossi D; Solfietti L; Fenoglio R; Menegatti E; Baldovino S Oncotarget; 2017 Jun; 8(25):41764-41777. PubMed ID: 28454112 [TBL] [Abstract][Full Text] [Related]
16. Treatment with pegylated interferon and ribavirin for hepatitis C virus-associated severe cryoglobulinemia in a liver/kidney transplant recipient. Montalbano M; Pasulo L; Sonzogni A; Remuzzi G; Colledan M; Strazzabosco M J Clin Gastroenterol; 2007 Feb; 41(2):216-20. PubMed ID: 17245223 [TBL] [Abstract][Full Text] [Related]
17. Antiviral therapy of symptomatic HCV-associated mixed cryoglobulinemia: meta-analysis of clinical studies. Fabrizi F; Dixit V; Messa P J Med Virol; 2013 Jun; 85(6):1019-27. PubMed ID: 23588727 [TBL] [Abstract][Full Text] [Related]
18. Recent news in the treatment of hepatitis B virus-related cryogobulinemic vasculitis. Mazzaro C; Dal Maso L; Visentini M; Ermacora A; Tonizzo M; Gattei V; Andreone P Minerva Med; 2020 Dec; 111(6):566-572. PubMed ID: 32573522 [TBL] [Abstract][Full Text] [Related]
19. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Landau DA; Rosenzwajg M; Saadoun D; Trébeden-Negre H; Klatzmann D; Cacoub P Arthritis Rheum; 2008 Sep; 58(9):2897-907. PubMed ID: 18759287 [TBL] [Abstract][Full Text] [Related]
20. Long-term effects of the new direct antiviral agents (DAAs) therapy for HCV-related mixed cryoglobulinaemia without renal involvement: a multicentre open-label study. Mazzaro C; Dal Maso L; Quartuccio L; Ghersetti M; Lenzi M; Mauro E; Bond M; Casarin P; Gattei V; Crosato IM; De Vita S; Pozzato G Clin Exp Rheumatol; 2018; 36 Suppl 111(2):107-114. PubMed ID: 29465371 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]